Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: Safety of intravitreal treatment for vascular homeostasis

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 5, 2011, Pages 471-475

  MacHalińska, Anna ^a   Paczkowska, Edyta ^a   Pabin, Tomasz ^a   Safranow, Krzysztof ^a   Karczewicz, Danuta ^a   MacHaliński, Boguslaw ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; HYPOXIA INDUCIBLE FACTOR; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

AGED; ARTICLE; BLOOD SAMPLING; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION; TISSUE OXYGENATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054849404     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0091     Document Type: Article

References (18)

1. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006. (Pubitemid 44511557)
2. Gaudreault, J., Fei, D., Rusit, J., et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46: 726-733, 2005. (Pubitemid 40270359)
3. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182, 2007. (Pubitemid 350181137)
4. Gamulescu, M.A., and Helbig, H. Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J. Ocul. Pharmacol. Ther. 26:213-216, 2010.
5. Hunting, C.B., Noort, W.A., and Zwaginga, J.J. Circulating endothelial (progenitor) cells reflect the state of the endothelium: Vascular injury, repair and neovascularization. Vox Sang. 88:1-9, 2005.
6. Miller-Kasprzak, E., and Jagodziń ski, P.P. Endothelial progenitor cells as a new agent contributing to vascular repair. Arch. Immunol. Ther. Exp. 55:247-259, 2007. (Pubitemid 47262710)
7. Prater, D.N., Case, J., Ingram, D.A., et al. Working hypothesis to redefine endothelial progenitor cells. Leukemia 21:1141-1149, 2007. (Pubitemid 46831802)
8. Nö r, J.E., Christensen, J., Mooney, D.J., et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:375-384, 1999. (Pubitemid 29094088)
9. Schmidt-Erfurth, U. Clinical safety of ranibizumab in agerelated macular degeneration. Expert Opin. Drug Saf. 9:149-165, 2010.
10. Rosenfeld, P.J., Rich, R.M., and Lalwani, G.A. Ranibizumab: Phase III clinical trialresults. Ophthalmol. Clin. North Am. 19:361-372, 2006. (Pubitemid 44279358)
11. Alexander, S.L., Linde-Zwirble, W.T., Werther, W., et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 114:2174-2178, 2007. (Pubitemid 350181138)
12. Kourlas, H., and Abrams, P. Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin. Ther. 29:1850-1861, 2007. (Pubitemid 350214458)
13. Tuñón, J., Ruiz-Moreno, J.M., Martín-Ventura, J.L., et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv. Ophthalmol. 54:339-348, 2009.
14. Pellé, G., Shweke, N., Van Huyen, J.P., et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am. J. Kidney Dis. 57: 756-759, 2011.
15. Wu, Z., and Sadda, S.R. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: A case report. Ann. Acad. Med. Singapore 37:591-593, 2008.
16. Matsuyama, K., Ogata, N., Matsuoka, M., et al. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br. J. Ophthalmol. 94:1215-1218, 2010.
17. Abouammoh, M., and Sharma, S. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 22:152-158, 2011.
18. Csaky, K., and Do, D.V. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am. J. Ophthalmol. 148:647-656, 2009.